Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotechnology companies like Biodexa Pharmaceuticals (BDRX) generate SEC filings that differ substantially from those of commercial-stage businesses. With no product revenue, the company's quarterly and annual reports focus primarily on clinical development progress, cash burn rates, and financing activities rather than sales metrics.
Biodexa's 10-K annual reports and 10-Q quarterly reports provide detailed disclosure of clinical trial progress, regulatory interactions, and research and development expenditures. For investors tracking eRapa's Phase 3 Serenta trial, these filings offer the most comprehensive updates on patient enrollment, trial timelines, and anticipated data readout periods. The Management's Discussion and Analysis section typically addresses clinical milestones achieved, regulatory designations obtained, and upcoming catalysts. Financial statement footnotes detail grant funding received, collaboration agreements, and contingent liabilities related to licensing arrangements.
Because Biodexa operates as a UK-based company trading via American Depositary Receipts, some disclosures may reference both US GAAP and international reporting standards. The company files as a foreign private issuer, which affects certain disclosure requirements and filing deadlines.
Form 8-K filings announce material events including clinical trial results, regulatory decisions, financing transactions, and collaboration agreements. For a clinical-stage biotech, these current reports often contain the most market-moving information. Positive Phase 2 or Phase 3 data releases, FDA approvals of Investigational New Drug applications, or notices of allowance for key patents would appear in 8-K filings.
Given Biodexa's small market capitalization and clinical stage, insider trading reports (Form 4) may reveal whether executives and directors maintain confidence in the company's prospects through personal share purchases. In biotechnology, insider buying ahead of anticipated clinical data or regulatory decisions sometimes signals management's expectations, though it remains an imperfect indicator.
Proxy statements (DEF 14A) disclose executive compensation structures, which for clinical-stage biotechs often include substantial stock option grants tied to achievement of clinical and regulatory milestones. These filings reveal the incentive framework aligned with bringing drugs through development.
Tracking Biodexa's SEC filings provides essential context for understanding the company's clinical progress, financial runway, and pathway toward potential regulatory approval and commercialization of its rare disease treatments.
Biodexa Pharmaceuticals is registering 929,878,200,000 Ordinary Shares, in the form of American Depositary Shares (Depositary Shares), for a best-efforts public offering. The deal comprises 157,000 Units at $3.28 per Unit, each with one Depositary Share and two Series L Warrants, plus up to 2,891,781 Pre-Funded Units at $3.2799 each, with a Pre-Funded Warrant and two Series L Warrants. Each Series L Warrant is immediately exercisable at $3.28 for five years; each Pre-Funded Warrant is exercisable at $0.0001 per Depositary Share without expiry, subject to 4.99% or 9.99% beneficial ownership caps.
If all Units are sold, Biodexa estimates net proceeds of about $8.75 million, to be used to fund its development programs, working capital and general corporate purposes. Ordinary Shares outstanding are expected to rise from 68,178,708,922 to 83,878,708,922 after the offering, before any warrant exercises. The company highlights that this equity raise and potential future warrant exercises may significantly dilute existing holders and pressure the trading price.
Biodexa Pharmaceuticals PLC filed a prospectus supplement tied to a resale registration for up to 341,352,000,000 ordinary shares, represented by 3,413,520 American Depositary Shares. The company also describes a best efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including warrants with an exercise price of $3.28 per ADS. Net proceeds from this offering are expected to be about $8.75 million, to fund development programs, working capital and general corporate purposes. As of September 30, 2025, Biodexa reported unaudited cash and cash equivalents of £2.79 million and notes that, after the offering and before any warrant exercises, 83,878,708,922 ordinary shares will be outstanding.
Biodexa Pharmaceuticals filed a prospectus supplement covering the resale by existing shareholders of up to 109,800,000 ordinary shares represented by 1,098 American Depositary Shares. The company also commenced a best efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including one ADS or pre-funded warrant plus two Series L warrants, at combined prices of $3.28 and $3.2799 per unit. Net proceeds from this offering are expected to be approximately $8.75 million to fund development programs, working capital and other general corporate purposes, with closing anticipated on or about December 19, 2025. As of September 30, 2025, cash and cash equivalents were £2.79 million, and after the offering the company expects to have 83,878,708,922 ordinary shares outstanding, assuming no warrant exercises.
Biodexa Pharmaceuticals PLC files a prospectus supplement covering the resale of up to 171,700,000 ordinary shares, represented by 1,717 American Depositary Shares (ADSs). Alongside this, the company has launched a best-efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including warrants. The offering is expected to generate approximately $8.75 million in net proceeds, which the company plans to use to fund its development programs, working capital and general corporate purposes. As of September 30, 2025, Biodexa reported cash and cash equivalents of £2.79 million, and assuming the offering closes with no warrant exercises, it will have 83,878,708,922 ordinary shares outstanding.
Biodexa Pharmaceuticals PLC supplements its resale prospectus covering up to 4,349,000,000 ordinary shares, represented by 43,490 American Depositary Shares (ADSs), that may be sold from time to time by existing shareholders. Alongside this, the company has begun a best efforts public offering of 157,000 ADS units, each with one ADS and two Series L warrants, and 2,891,781 pre-funded units, each with a pre-funded warrant and two Series L warrants, at combined prices of $3.28 and $3.2799 per unit, respectively.
The offering is expected to generate approximately $8.75 million in net proceeds, which the company plans to use for development programs, working capital and general corporate purposes. As of September 30, 2025, Biodexa reported cash and cash equivalents of £2.79 million83,878,708,922 ordinary shares outstanding. New Series L and pre-funded warrants carry exercise caps at 4.99% or 9.99% beneficial ownership to limit concentration.
Biodexa Pharmaceuticals is registering for resale up to 2,846,100,000 ordinary shares, represented by 24,861 American Depositary Shares (ADSs), held by existing shareholders. Separately, the company has begun a best efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including ADSs or pre-funded warrants plus two Series L warrants. Unit pricing is $3.28 per ADS unit and $3.2799 per pre-funded unit, with Series L warrants exercisable at $3.28 for five years and pre-funded warrants at $0.0001 per ADS. Net proceeds from this primary offering are expected to be about $8.75 million, intended for development programs, working capital and general corporate purposes. As of September 30, 2025, the company reported £2.79 million in cash and cash equivalents and later settled a previously disclosed advisor fee dispute via a payment. Assuming the offering closes and no warrants are exercised, 83,878,708,922 ordinary shares will be outstanding.
Biodexa Pharmaceuticals PLC has launched a best efforts public offering of 157,000 ADS Units and 2,891,781 Pre-Funded Units, each unit combining one ADS or pre-funded warrant with two Series L warrants. The company expects net proceeds of about $8.75 million, to be used to fund development programs, working capital and other general corporate purposes, with closing anticipated on or about December 19, 2025.
The Pre-Funded Warrants are exercisable at $0.0001 per ADS, while the Series L and related placement agent warrants are exercisable at $3.28 per ADS and expire five years after issuance, subject to 4.99% or 9.99% beneficial ownership limits. As of September 30, 2025, the company reported unaudited cash and cash equivalents of £2.79 million, and after the offering closes, it expects to have 83,878,708,922 ordinary shares outstanding assuming no warrant exercises.
Biodexa Pharmaceuticals PLC is registering up to 5,923,377,900,000 Ordinary Shares in the form of American Depositary Shares to support a best-efforts public offering of up to 3,536,345 Units or Pre-Funded Units. Each Unit includes one Depositary Share (representing 100,000 Ordinary Shares) and one Series L warrant with an initial exercise price set at 225% of the Unit price, plus complex reset and "zero cash exercise price" features that can sharply increase shares issued without bringing in additional cash.
The company estimates net proceeds of about $15.5 million if all Units are sold, to fund its drug development programs, working capital and general corporate purposes. As of December 1, 2025, it had 68,178,708,922 Ordinary Shares outstanding, and if all Ordinary Shares offered were issued they would equal roughly 98.9% of that total, meaning very high potential dilution. Biodexa is a clinical-stage biotech focused on eRapa for familial adenomatous polyposis and non‑muscle invasive bladder cancer, tolimidone for type 1 diabetes, and MTX110 for rare brain cancers, with eRapa already in a Phase 3 FAP trial and supported by a $3.0 million CPRIT grant and FDA fast track status. Cash and cash equivalents were £2.79 million as of September 30, 2025, based on unaudited figures.
Biodexa Pharmaceuticals PLC is registering 109,800,000 Ordinary Shares represented by 1,098 Depositary Shares for resale by holders of Series D warrants issued in a June 2023 private placement. The company is not selling any Depositary Shares in this offering and will not receive proceeds from shareholder resales, although it could receive up to
Ordinary Shares outstanding were 61,952,308,922 as of
As of
FAQ
What is the current stock price of Biodexa Pharmaceuticals plc (BDRX)?
What is the market cap of Biodexa Pharmaceuticals plc (BDRX)?
